Threat actors in Latin America have begun to use AI agents to facilitate their entire attack chains, from assisting with initial access to generating penetration tools on the fly — and organizations ...

Minecraft master Craftee collects unpredictable lucky hearts that grant random powers. ‘Trust has been lost’: Jane Hume reflects on by-election loss as voters 'sent a message’ Electric cars have a ...

A lot of thought goes into naming a racehorse. Some people take inspiration from the horse’s pedigree, while others make it more personal, naming the horse after something special to the owner: a ...

The tool can find one’s name (or any other text) among the vast geological structures of Earth. For example, the letters that make up ‘The Hindu’ can resemble a firn-filled Fjord in Tibet or Lake ...

One of the best parts of the Kentucky Derby is listening to Travis Stone, the Churchill Downs Racetrack announcer, rapidly list off the name of each Kentucky Derby horse. So, what is your Kentucky ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Firefly custom models analyze your assets to preserve character designs and emulate illustration and photography styles. Firefly custom models analyze your assets to preserve character designs and ...

Josh Finan, the rising British star best known for his recent TV work on shows such as “The Responder” (for which he was BAFTA TV nominated), “The Gentleman,” “Say Nothing” (playing Gerry Adams) and ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...